StockData
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK) stock

STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30177% above fair value
$26.69+0.28 (+1.06%)

Close on Nov 18, 2026Market cap $1.72BP/E –Yield –

Stoke Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Stoke Therapeutics's pe ratio was 45.3× on Jan 30, 2026.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jan 30, 202645.3×−2.1
2025Dec 31, 202547.4×–

More Stoke Therapeutics figures

See a number that looks wrong?